Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts coverage on Dr Martens at 'buy'

(Sharecast News) - Analysts at Berenberg initiated coverage on iconic bootmaker Dr Martens on Thursday with a 'buy' rating and 102.0p price target, noting that the business had both "global appeal and clear growth potential". Berenberg said Dr Martens was a "distinctive footwear brand" with global relevance that stretches far beyond its workwear and counter-cultural roots in the UK.

"We estimate that slightly less than 18% of Dr Martens' total revenues are generated in the UK, where it has circa 1% share of the total footwear market," said the analysts. "On a global basis, we estimate that Dr Martens has only 0.0003% market share and we think that there is clear scope to build its presence further worldwide."

The German bank said the brand itself had "a high level of awareness", as 74% of consumers in the markets in which the company trades said they were aware of it, with brand awareness highest in the UK at 92%, versus 73% in the US and 53% in Japan.

"Dr Martens favours a direct-to-consumer approach but also values the wholesale distribution channel. The company's expansion from its current reach could include circa 15 new stores pa for DTC, together with new wholesale partnerships," said Berenberg, which also pointed out that large countries and regions such as India, South Africa and the Middle East represent "virgin territory" for the company.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.